Oticara is an emerging, clinical-stage pharmaceutical company developing innovative therapies to improve the quality of life for patients with chronic inflammatory sinus conditions. The company’s lead product is the only sterilizable, nasal-mucosa-optimized steroid cream, administered by Ear, Nose and Throat (ENT) physicians via a custom applicator. This patient-friendly, single-dose in-office therapy delivers lasting relief for chronic rhinosinusitis (CRS) patients and is designed to focus steroid locally and limit systemic exposure compared to oral steroids. Clinical studies have demonstrated rapid and sustained symptom improvement, even amongst patients whose symptoms have not been controlled by available therapies. With an initial focus on post-surgical CRS patients, Oticara is advancing a new treatment option for one of the most difficult-to-treat populations in ENT. Learn more at oticara.com.

Oticara Pharmaceuticals

Org chart

Teams

Offices